Featured Research

from universities, journals, and other organizations

Adelaide Scientists Make HIV A Safe Aid In Gene Therapy

Date:
November 20, 2001
Source:
Women's And Children's Hospital, Adelaide
Summary:
Senior researcher Dr Don Anson and PhD student Maria Fuller from the Women’s and Children’s Hospital, Adelaide have published a paper in Human Gene Therapy in which they have shown that Human Immunodeficiency Virus Type 1 (HIV-1), after modification can be safely used to transfer therapeutic genes into human cells without transferring the disease.

November 19, 2001 -- Viruses have evolved , over thousands of years, to overcome our bodies’ defenses against viral infection. Once they gain a hold in our bodies, viruses can skillfully transfer their genetic material into our cells, combining it with our own genetic material and causing infection.

Many human diseases result from missing or damaged genes in our cells. Such abnormal or missing genes can potentially be replaced by ‘normal’ genes using the technique of ‘Gene Therapy’, thus overcoming the disease.

Senior researcher Dr Don Anson and PhD student Maria Fuller from the Women’s and Children’s Hospital, Adelaide have today published a paper in Human Gene Therapy in which they have shown that Human Immunodeficiency Virus Type 1 (HIV-1), after modification can be safely used to transfer therapeutic genes into human cells without transferring the disease.

“Viruses are very good at transferring their genetic material into cells, so it is logical to use them to carry any therapeutic genes we want to get into those same cells. HIV-1 is particular suited to this purpose, because, firstly, the genetic material transferred becomes a permanent part of the host cell, and secondly because it transfers genetic material to cells that are not growing and not all viruses can do this – and it is these non growing cells that we need to target with therapeutic genes,” Dr Anson says.

“However to use HIV-1 for this purpose we must be sure it cannot infect our cells and cause AIDS. We are now able to modify HIV’s genetic material so those viral proteins essential for it to reproduce and cause disease in our cells are removed.”

Other groups worldwide have also been working on gene transfer using HIV-1, but Dr Anson’s group has developed a method to vastly increase the safety with which HIV-1 can be used to transfer genes without causing disease.

Currently animal models of genetic disease are being studied using this approach before the methods can be taken to trials of human disease.

The use of this HIV-1 transfer approach has wide applicability for a variety of human genetic diseases.

This work was supported by the National Health and Medical Research Council.


Story Source:

The above story is based on materials provided by Women's And Children's Hospital, Adelaide. Note: Materials may be edited for content and length.


Cite This Page:

Women's And Children's Hospital, Adelaide. "Adelaide Scientists Make HIV A Safe Aid In Gene Therapy." ScienceDaily. ScienceDaily, 20 November 2001. <www.sciencedaily.com/releases/2001/11/011120043248.htm>.
Women's And Children's Hospital, Adelaide. (2001, November 20). Adelaide Scientists Make HIV A Safe Aid In Gene Therapy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/11/011120043248.htm
Women's And Children's Hospital, Adelaide. "Adelaide Scientists Make HIV A Safe Aid In Gene Therapy." ScienceDaily. www.sciencedaily.com/releases/2001/11/011120043248.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins